Eg5 inhibitor YL001 induces mitotic arrest and inhibits tumor proliferation-Reference-Cited by-同舟云学术

Eg5 inhibitor YL001 induces mitotic arrest and inhibits tumor proliferation

Published:2017-04-18 Issue:26 Volume:8 Page:42510-42524
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Wang Yufei¹²,Wu Xingyu¹,Du Mufeng¹,Chen Xi¹,Ning Xianling¹,Chen Hong¹,Wang Siyuan¹,Liu Jia¹,Liu Zhenming²,Li Ridong¹,Fu Ge²,Wang Chunguang²,McNutt Michael A.¹,Zhou Demin²,Yin Yuxin¹

Affiliation:

1. Institute of Systems Biomedicine, State Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Tumor Systems Biology, Department of Pathology, School of Basic Medicine, Peking-Tsinghua Center for Life Sciences, Peking University Health Science Center, Beijing 100191, China

2. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non‐Covalent Interactions in the Self‐Assembly of Dihydropyridone Supramolecules and In Vitro Anti‐Cancer Assessment in Human Lung Adenocarcinoma Cell Line (A549);ChemPlusChem;2023-04

2. Advances in the discovery of DHPMs as Eg5 inhibitors for the management of breast cancer and glioblastoma: A review;Results in Chemistry;2023-01

3. Polyphenol MHQP as an allosteric inhibitor of Kinesin-5: Cease the molecular catwalk of “Drunken Sailor”;Indian Journal of Biochemistry and Biophysics;2023

4. REMOVED: Advances in the discovery of DHPMs as Eg5 inhibitors for the management of breast cancer;Dihydropyrimidinones as Potent Anticancer Agents;2023

5. Pyrrolotriazinone as an Underexplored Scaffold in Drug Discovery;Pharmaceuticals;2021-12-06